Skip to NavigationSkip to content


FDA approves Regeneron’s antibody Ebola treatment

Photo by CDC Global

The FDA has approved Regeneron’s antibody drug inmazeb for treating Ebola.

The treatment works through targeting the glycoprotein on the surface of the virus. Glycoproteins attach to the cell receptor and fuses with the viral and host cell membranes, allowing the virus to enter cells. The antibodies in the drug bind to these glycoproteins to block the attachment and the entry of the virus. 

European Commission announces approval for Janssen’s Ebola vaccine

Photo by NIAID

Johnson & Johnson announced that the European Commission has granted Marketing Authorisation for its Janssen Ebola vaccine.

Two Marketing Authorisation Applications (MAAs) were submitted to the European Medicines Agency (EMA) for the vaccines that are made up of Zabdeno and Mvabea. The MAAs also received a positive opinion by the EMA’s Committee for Medicinal Products for Human Use (CHMP) and is indicated for active immunisation and prevention of Ebola Virus Disease caused by the Zaire ebolavirus species in individuals aged one year and above.

Chinese company starts mass producing Gilead coronavirus drug

A drugmaker in China said it has started mass producing Gilead Sciences Ebola drug that has the potential to fight the coronavirus.

It will be developed by BrightGene Bio-Medical Technology. They said in a statement, filed to the Shanghai Stock Exchange,it has the technology to synthesize the active pharmaceutical ingredients of remdesivir, Gilead’s drug that is a leading candidate to treat the coronavirus.

Patient successfully treated for coronavirus in the US

Health officials in the US say they have successfully treated a man for coronavirus with an experimental drug.

The Ebola drug Remdesivir, made by Gilead Sciences, was given to an American who is 35 years old. The doctors reported that on 26 January his condition seemed to improve within a day, and by 30 January it had resolved most of the symptoms except a cough.

FDA warns Purell not to claim sanitizers prevent Ebola

The FDA has issued a warning letter to Purcell telling them to stop its misleading advertising of their sanitiser products.

The FDA says the Gojo Industries website, the parent company of Purcell, makes the claim the product can treat Ebola. They cite the Q&A section, and point to the question “is Purell advanced sanitizer effective against Ebola?”

Chinese coronavirus set to be put on international health emergency list

The World Health Organisation (WHO) is expected to trigger a Public Health Emergency over the Wuhan coronavirus outbreak, meaning it will join the likes of Polio, Ebola and Swine Flu. It would be only the fifth time such an emergency as been declared.

So far nine people have been killed due to complications around the illness, with 440 cases being reported across China, Japan, the US and South Korea.

FDA approves Merck & Co’s Ebola vaccine

The FDA has approved Merck & Co’s Ebola vaccine, Ervebo. This marks the first time they have approved a vaccine against the virus.

It follows the company getting approval from the European Commission to market Ervebo back in November. The vaccine is administered through a single-dose to prevent EVD caused by Ebola in patients aged 18 or older.

Ervebo has already been used by the World Health Organisation (WHO) and the Democratic Republic of the Congo (DRC) to help reduce Ebola outbreaks during the West African epidemic from 2013-2016.

Johnson & Johnson to support Rwanda’s preparations against Ebola outbreak

Johnson & Johnson will provide up to 200,000 Ebola vaccines to the Republic of Rwanda, through its pharmaceutical subsidiary Janssen.

This is being implemented due to the current threat from the neighbouring country of the Democratic Republic of the Congo (DRC), which is currently experiencing its own Ebola outbreak.

MSD secures EU approval for its Zaire Ebola vaccine Ervebo

MSD has scored approval from the European Commission for Ervebo, the company’s Zaire Ebola vaccine, for the prevention of Ebola virus disease (EVD) in patients at least 18 years old, it has emerged.              

The decision follows a positive recommendation from the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) in October. The vaccine is currently under review in the US under the FDA’s priority review pathway, with a final decision due by 14 March 2020.

J&J to supply 500,000 Ebola vaccines to fight DR Congo outbreak

Johnson & Johnson has reached an agreement with the Government of the Democratic Republic of the Congo (DRC) to supply up to 500,000 regimens of its Ebola virus vaccine in an effort to aid an expanded public health initiative to help battle the ongoing outbreak of the disease in the country.

The current outbreak in DRC is the second-worst on record after the 2014-2016 West Africa epidemic; to date, more than 3,000 cases have been reported and 2,000 patients have died.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches